John Whelan: Irish pharma pushes back against EU plans

According to the IPHA, the proposals from the Commission will weaken intellectual property rights and degrade the development and delivery of innovative new medicines for patients in Europe.

Considering that the pharmaceutical industry contributes more to Ireland’s trade balance than any other sector, the European Commission’s radical proposals for the sector have the industry here and across the rest of Europe dismayed and more than a little upset.

According to the business group Irish Pharmaceutical Healthcare Association, or IPHA, the proposals from the Commission will weaken intellectual property rights and degrade the development and delivery of innovative new medicines for patients in Europe.